The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Both the India and GCC entities will be operated by separate dedicated management teams
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Evinova will operate as a separate health-tech business within AstraZeneca
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Phase 3 data expected in the second half of 2024
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Subscribe To Our Newsletter & Stay Updated
